When Is Wegovy Available on the NHS — and What Are Your Options Now?

What NICE actually decided (and why supply hasn't followed demand

NICE published its appraisal of semaglutide for weight management (TA875) on 8 March 2023, recommending Wegovy for adults with a BMI of at least 35 and at least one weight-related comorbidity) conditions such as type 2 diabetes, high blood pressure, or obstructive sleep apnoea. Ethnic background adjustments apply: the threshold falls by 2.5 kg/m² for people of South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. You can read the full recommendation criteria in NICE's appraisal of semaglutide (TA875) directly.

There is, however, a structural catch. NICE tied its recommendation to use within a specialist weight management service offering multidisciplinary support, not a GP appointment or a standard referral. If you want to understand whether Wegovy is available on the NHS and what that actually means in practice, the two-year treatment maximum and the capacity constraints built into the appraisal go a long way to explaining the gap. The NICE guidance also says treatment should be reviewed and potentially stopped if weight loss is less than 5% after six months at the maintenance dose.

The result is a gap between what is legally available and what people can practically access. Being eligible on paper does not place you at the front of a queue; it places you at the back of one.

How NHS Wegovy access actually works in practice

Referrals to specialist weight management services go through your GP. If your BMI and health conditions meet the TA875 thresholds, your GP can refer you, but the specialist service then assesses you, and waiting times vary widely by area. NHS England's guidance on weight-management injections is worth reading if you want to understand what the wraparound diet and activity support looks like, and what you'd be committing to.

One quick check you can do in under a minute: search your integrated care board's website for "tier 3 weight management" or "specialist weight service referral", most publish current waiting-time information, and if you're trying to work out when Wegovy will realistically become available on the NHS in your area, the gap between expectation and reality often becomes clear immediately.

Scotland, Wales and Northern Ireland run their own access pathways with different thresholds and timelines. If you're based in Scotland, the criteria and routes are covered separately on our Scotland-specific Wegovy NHS page. For an overview of semaglutide's NHS status across the UK, this guide covers how semaglutide sits within the NHS broadly.

Tirzepatide on the NHS, a newer route opening up

Wegovy is not the only option to understand here. NICE recommended tirzepatide (Mounjaro) in December 2024 (TA1026), and NHS England began rolling it out from June 2025, with a second cohort activated in June 2026. The phased rollout started with those at BMI 40 or above with four or more qualifying conditions, and is expanding gradually. From April 2026, some GP practices are also able to prescribe tirzepatide under the 2026/27 GP contract, though practice participation is optional, so availability varies. If you're curious about how that picture compares, our guide on NHS access for GLP-1 weight-loss medicines sets it out side by side.

It is worth being clear: tirzepatide and semaglutide are different medicines with different trial evidence behind them. Neither is automatically superior for every individual; that is a clinical conversation, not a content page decision.

Private treatment as a practical alternative, and how to do it safely

For people who meet the clinical criteria but face a long NHS wait, a private prescription from a GPhC-registered online pharmacy is a legal and regulated path. The consultation, clinical assessment, and ongoing prescriber review that would happen in an NHS setting must still happen, the key difference is timing and who pays.

What to look for: any pharmacy supplying Wegovy or Mounjaro must be registered with the General Pharmaceutical Council. You can verify any online pharmacy in seconds on the GPhC's public register. If a seller offers these medicines without a formal clinical assessment, that is a serious red flag, the MHRA has warned repeatedly about counterfeit weight-loss pens circulating online, some containing dangerous substances. Supply without proper clinical oversight is not a grey area.

At nume, every consultation is read by a GPhC-registered Independent Prescriber the same day, a clinician, not automated software. If you're approved and order by midday, treatment is dispatched the same day and arrives free the next working day via DPD. There are no subscriptions; every repeat order goes through the same clinical re-review. Our Wegovy treatment page covers what's included and what the process looks like from start to finish. For a broader look at your options, our weight-loss treatments overview is a good starting point.

If you'd like to find out whether you're clinically suitable, start your free consultation and a prescriber will review your answers the same day.